Guang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guang Yang has a total of 379 co-authors. Here are the top co-authors by number of shared publications:
Shuangwei Liu
17 shared publications- Cheng Yang
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai-Baiyang Joint R&D Center for Basic and Translational Medicine of Organ Fibroproliferation, Nankai University
16 shared publications Ning Liu
16 shared publicationsCheng Yang
15 shared publicationsMingming Wei
The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy
14 shared publicationsKun Zhang
13 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in Cell Reports Medicine
XPO5 regulates ferroptosis via MITF-ACSL4 signaling to drive CRPC progression and serves as a druggable target
- 12 November 2026
- Published by Elsevier in Cell Reports Medicine
Open AccessXPO5 regulates ferroptosis via MITF-ACSL4 signaling to drive CRPC progression and serves as a druggable target
- 23 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 26135-26162
Rational Design of Potent and Highly Selective FGFR1 Irreversible Inhibitors Guided by Molecular Dynamics Simulations
Molecular dynamics (MD) simulations revealed distinct P-loop conformational differences in the ATP-binding domain between FGFR1 and other FGFR subtypes. A conformation-restricted linker optimization strategy was applied to identify a potent and selective irreversible FGFR1 inhibitor (compound 24). MD models demonstrated that the covalent warhead of compound 24 retained an optimal distance and orientation toward the P-loop cysteine of FGFR1, facilitating efficient Michael addition. After covalent conjugation, compound 24 interacted with the hinge region and precisely matched the unique FGFR1 conformation. Its robust antitumor activity was validated in cellular, CDX, and PDX models by suppressing FGFR1-dependent tumor growth, providing a novel strategy for subtype-selective FGFR1 inhibitor development.
- 23 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 26135-26162
Rational Design of Potent and Highly Selective FGFR1 Irreversible Inhibitors Guided by Molecular Dynamics Simulations
Molecular dynamics (MD) simulations revealed distinct P-loop conformational differences in the ATP-binding domain between FGFR1 and other FGFR subtypes. A conformation-restricted linker optimization strategy was applied to identify a potent and selective irreversible FGFR1 inhibitor (compound 24). MD models demonstrated that the covalent warhead of compound 24 retained an optimal distance and orientation toward the P-loop cysteine of FGFR1, facilitating efficient Michael addition. After covalent conjugation, compound 24 interacted with the hinge region and precisely matched the unique FGFR1 conformation. Its robust antitumor activity was validated in cellular, CDX, and PDX models by suppressing FGFR1-dependent tumor growth, providing a novel strategy for subtype-selective FGFR1 inhibitor development.
- 24 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7756-7781
Discovery of a Selective DNMT1 Degrader with a Unique Molecular Glue Mechanism as a Potential Therapeutic Agent for Acute Myeloid Leukemia
Previous research indicated that DNA methyltransferase 1 (DNMT1) inhibitors can induce UHRF1-mediated degradation of the DNMT1 protein. However, the underlying degradation mechanism remains poorly understood. During our investigation of a series of quinazoline-based DNMT1 inhibitors, we serendipitously discovered a highly potent and selective DNMT1 degrader 6k. Employing techniques such as surface plasmon resonance (SPR) and molecular dynamics (MD) simulations, we have for the first time clearly demonstrated that 6k can promote a significant direct interaction between DNMT1 and UHRF1 proteins via a molecular glue mechanism under cell-free conditions. Further biological evaluations indicated that this DNMT1 degrader exhibits potent inhibitory effects on AML cells both in vitro and in vivo. The results show that compound 6k effectively suppresses the proliferation of primary AML cells and significantly extends the survival of experimental animals in the patient-derived xenograft (PDX) model. More importantly, 6k demonstrates favorable bioavailability and safety profiles, suggesting its promising potential for further development.
- 24 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7756-7781
Discovery of a Selective DNMT1 Degrader with a Unique Molecular Glue Mechanism as a Potential Therapeutic Agent for Acute Myeloid Leukemia
Previous research indicated that DNA methyltransferase 1 (DNMT1) inhibitors can induce UHRF1-mediated degradation of the DNMT1 protein. However, the underlying degradation mechanism remains poorly understood. During our investigation of a series of quinazoline-based DNMT1 inhibitors, we serendipitously discovered a highly potent and selective DNMT1 degrader 6k. Employing techniques such as surface plasmon resonance (SPR) and molecular dynamics (MD) simulations, we have for the first time clearly demonstrated that 6k can promote a significant direct interaction between DNMT1 and UHRF1 proteins via a molecular glue mechanism under cell-free conditions. Further biological evaluations indicated that this DNMT1 degrader exhibits potent inhibitory effects on AML cells both in vitro and in vivo. The results show that compound 6k effectively suppresses the proliferation of primary AML cells and significantly extends the survival of experimental animals in the patient-derived xenograft (PDX) model. More importantly, 6k demonstrates favorable bioavailability and safety profiles, suggesting its promising potential for further development.
- Open Access
- 11 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (6) , 3764-3783
Lactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors
- 11 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (6) , 3764-3783
Open AccessLactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors
- 31 January 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 307, 118617
Structural optimization of AR and AR-V7 degraders incorporating silicon-based hydrophobic tags for treatment of castration-resistant prostate cancer
- 31 January 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 307, 118617
Structural optimization of AR and AR-V7 degraders incorporating silicon-based hydrophobic tags for treatment of castration-resistant prostate cancer
- 20 November 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 243, 564
Corrigendum to “Fibroblast growth factor receptor inhibitors ameliorate metabolic dysfunction-associated steatohepatitis by modulating the glycine-glutathione-gut microbiota axis” [Free Rad. Biol. Med. 240 (2025) 410–425]
- 20 November 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 243, 564
Corrigendum to “Fibroblast growth factor receptor inhibitors ameliorate metabolic dysfunction-associated steatohepatitis by modulating the glycine-glutathione-gut microbiota axis” [Free Rad. Biol. Med. 240 (2025) 410–425]
- 28 October 2025
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (67) , e01379
Discovery of a Potent Lysine‐Specific Histone Demethylase‐1 (LSD‐1) Inhibitor for Cancer Treatment via Machine Learning, Molecular Modeling, and In Vitro Validation
The discovery of potent lysine‐specific histone demethylase 1 (LSD‐1) inhibitors is of significant importance in cancer therapy, as LSD‐1 overexpression contributes to tumour progression and malignancy through the regulation of gene expression. We employed an integrated strategy that combined machine learning‐based virtual screening, bioassay validation, and ligand–target interaction analysis. Virtual screening identified 29 candidate compounds, of which 17 demonstrated micromolar‐level enzymatic inhibition in experimental assays. Among them, compound L01 showed strong potential as an LSD‐1 inhibitor, exhibiting significant antileukemic activity ( IC 50 = 24 µM) and confirmed binding to LSD‐1 in Kasumi‐1 cells. MST and SPR analysis confirmed the direct binding between L01 and LSD‐1 inferred from our in vitro studies. Molecular docking and molecular dynamics simulations further supported the interaction, revealing a binding affinity of L01 comparable to that of the well‐characterised reversible inhibitor SP‐2577. ADMET analysis revealed that L01 possesses excellent Caco‐2 permeability and high target specificity; however, its moderate drug‐likeness and potential toxicity issues underscore the need for further optimisation. Through computational modelling and experimental validation, our study identifies L01 as a promising LSD‐1 inhibitor with strong potential for optimisation to improve bioavailability and safety in cancer therapy.
- 28 October 2025
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (67) , e01379
Discovery of a Potent Lysine‐Specific Histone Demethylase‐1 (LSD‐1) Inhibitor for Cancer Treatment via Machine Learning, Molecular Modeling, and In Vitro Validation
The discovery of potent lysine‐specific histone demethylase 1 (LSD‐1) inhibitors is of significant importance in cancer therapy, as LSD‐1 overexpression contributes to tumour progression and malignancy through the regulation of gene expression. We employed an integrated strategy that combined machine learning‐based virtual screening, bioassay validation, and ligand–target interaction analysis. Virtual screening identified 29 candidate compounds, of which 17 demonstrated micromolar‐level enzymatic inhibition in experimental assays. Among them, compound L01 showed strong potential as an LSD‐1 inhibitor, exhibiting significant antileukemic activity ( IC 50 = 24 µM) and confirmed binding to LSD‐1 in Kasumi‐1 cells. MST and SPR analysis confirmed the direct binding between L01 and LSD‐1 inferred from our in vitro studies. Molecular docking and molecular dynamics simulations further supported the interaction, revealing a binding affinity of L01 comparable to that of the well‐characterised reversible inhibitor SP‐2577. ADMET analysis revealed that L01 possesses excellent Caco‐2 permeability and high target specificity; however, its moderate drug‐likeness and potential toxicity issues underscore the need for further optimisation. Through computational modelling and experimental validation, our study identifies L01 as a promising LSD‐1 inhibitor with strong potential for optimisation to improve bioavailability and safety in cancer therapy.
- 23 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302
Natural products harboring Michael receptors: A focus on targeting cancer stem cells
- 23 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302
Natural products harboring Michael receptors: A focus on targeting cancer stem cells
- 24 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (817) , eadt9100
USP5 inhibition enables potential therapy for t(8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenografts
The AML1-ETO (AE) fusion protein is a key target for treating t(8;21) acute myeloid leukemia (AML). In this investigation, we identified ubiquitin-specific protease 5 (USP5) as the deubiquitinating enzyme of AE. USP5 knockdown decreased AML cell growth and induced differentiation both in vitro and in vivo. In addition, we developed a high-throughput screening (HTS) method and identified a potent, selective USP5 inhibitor, WCY-8-67. This lead compound was identified as a selective USP5 inhibitor by targeting the ubiquitin-associated domain 2 (UBA2) region. It also induced aggregation and precipitation of the target protein, which led to USP5 dysfunction. WCY-8-67 exhibited excellent in vivo bioavailability and tolerability, and it effectively inhibited the growth of AML cells in animal models. In addition, in a patient-derived xenograft (PDX) model, this compound, when combined with 5-azacytidine (5-Aza), improved therapeutic effects. This study presents promising targeted therapeutic possibilities for the treatment of t(8;21) AML that require further study.
- 24 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (817) , eadt9100
USP5 inhibition enables potential therapy for t(8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenografts
The AML1-ETO (AE) fusion protein is a key target for treating t(8;21) acute myeloid leukemia (AML). In this investigation, we identified ubiquitin-specific protease 5 (USP5) as the deubiquitinating enzyme of AE. USP5 knockdown decreased AML cell growth and induced differentiation both in vitro and in vivo. In addition, we developed a high-throughput screening (HTS) method and identified a potent, selective USP5 inhibitor, WCY-8-67. This lead compound was identified as a selective USP5 inhibitor by targeting the ubiquitin-associated domain 2 (UBA2) region. It also induced aggregation and precipitation of the target protein, which led to USP5 dysfunction. WCY-8-67 exhibited excellent in vivo bioavailability and tolerability, and it effectively inhibited the growth of AML cells in animal models. In addition, in a patient-derived xenograft (PDX) model, this compound, when combined with 5-azacytidine (5-Aza), improved therapeutic effects. This study presents promising targeted therapeutic possibilities for the treatment of t(8;21) AML that require further study.
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20464-20486
Translational Research on the Oral Delivery of the Cytotoxic PROTAC Molecule via Tumor-Targeting Prodrug Strategy for Triple-Negative Breast Cancer Treatment
In the present work, we have identified a proteolysis targeting chimera (PROTAC) molecule that potently and selectively degrades CDK4, CDK6, and CDK9, inhibiting triple-negative breast cancer (TNBC) cell proliferation at low nanomolar concentrations. However, its low bioavailability and significant in vivo toxicity in experimental animals limit clinical translation. To address this challenge, we identified an oral bioavailable and tumor-targeting prodrug that substantially reduces systemic exposure of the PROTAC compound while enabling significant tumor-specific enrichment. This prodrug effectively and safely inhibits TNBC cell proliferation in multiple cell line-derived xenografts (CDX) and patient-derived xenograft (PDX) models, positioning it as a promising candidate for targeted TNBC therapy.
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20464-20486
Translational Research on the Oral Delivery of the Cytotoxic PROTAC Molecule via Tumor-Targeting Prodrug Strategy for Triple-Negative Breast Cancer Treatment
In the present work, we have identified a proteolysis targeting chimera (PROTAC) molecule that potently and selectively degrades CDK4, CDK6, and CDK9, inhibiting triple-negative breast cancer (TNBC) cell proliferation at low nanomolar concentrations. However, its low bioavailability and significant in vivo toxicity in experimental animals limit clinical translation. To address this challenge, we identified an oral bioavailable and tumor-targeting prodrug that substantially reduces systemic exposure of the PROTAC compound while enabling significant tumor-specific enrichment. This prodrug effectively and safely inhibits TNBC cell proliferation in multiple cell line-derived xenografts (CDX) and patient-derived xenograft (PDX) models, positioning it as a promising candidate for targeted TNBC therapy.